These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1347692)

  • 1. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
    Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
    [No Abstract]   [Full Text] [Related]  

  • 2. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
    Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
    [No Abstract]   [Full Text] [Related]  

  • 3. Total androgen ablation: American experience.
    Crawford ED; Nabors WL
    Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
    Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
    Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Venner PM; Tewari HD
    Prog Clin Biol Res; 1987; 243A():391-400. PubMed ID: 3116550
    [No Abstract]   [Full Text] [Related]  

  • 6. Total androgen ablation: Canadian experience.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
    Janknegt RA
    Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Complete androgen blockage in the treatment of metastatic prostate cancer].
    Matzkin H; Braf Z
    Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
    [No Abstract]   [Full Text] [Related]  

  • 9. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
    Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
    Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximal androgen blockade in prostatic cancer.
    Denis L
    Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
    [No Abstract]   [Full Text] [Related]  

  • 11. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
    Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
    Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
    [No Abstract]   [Full Text] [Related]  

  • 12. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 13. Total androgen blockade for metastatic cancer of the prostate.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM
    Am J Clin Oncol; 1988; 11 Suppl 2():S187-90. PubMed ID: 3149456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
    Beland G
    Urology; 1991; 37(2 Suppl):25-9. PubMed ID: 1992600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
    Hucher M; de Gery A; Bertagna C
    Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostatic cancer--what to do? Staging and prognostic factors in the primary therapy decision.
    Faul P
    Eur Urol; 1992; 22(2):89-98. PubMed ID: 1478236
    [No Abstract]   [Full Text] [Related]  

  • 19. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
    Navratil H
    Prog Clin Biol Res; 1987; 243A():401-10. PubMed ID: 3116551
    [No Abstract]   [Full Text] [Related]  

  • 20. [Metastatic cancer of the prostate: course, diagnosis and therapeutic management].
    Wisard M; Gabellon S
    Rev Med Suisse Romande; 1995 Mar; 115(3):241-7. PubMed ID: 7777765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.